$20bn acquisition of Genzyme by Sanofi delivers platform for growth

Feb. 24, 2011 - PRLog -- Sanofi-Aventis (Sanofi) is a global pharmaceutical company engaged in the research, development, manufacture and marketing of healthcare products. The company operates its business in two broad categories, namely, Pharmaceuticals and Vaccines. The Pharmaceutical segment of the company focuses on the development of products in the areas of cardiovascular diseases, thrombosis, diabetes, central nervous system (CNS), internal medicine and oncology. Sanofi offers Vaccines in pediatric combinations and poliomyelitis vaccines, influenza, adult and adolescent booster, meningitis as well as travel, endemic and measles, mumps, rubella (MMR) areas. Sanofi-Aventis is the world's fourth largest pharmaceutical group and Europe's second largest pharmaceutical player. The group operates in more than 100 countries. It is headquartered in Paris, France, and employed 104,867 people as of December 2009. The group recorded revenues of E30,749 million (approximately $42,883.5 million) during the financial year (FY) ended December 2009, an increase of 6.7% over FY2008. The operating profit of the group was E6,366 million (approximately $8,878.2 million) during FY2009, an increase of 44.9% over FY2008. The net profit of the group was E5,265 million (approximately $7,342.7 million) in FY2009, an increase of 36.7% over FY2008.

Genzyme Corporation (Genzyme) is a biotechnology company which is principally engaged in developing and applying technologies to encounter unmet deadly diseases. Its products and services are focused on rare genetic disorders, kidney diseases, orthopedics, organ transplant, cancer, diagnostic and predictive testing. The company has its operations worldwide with its principal concentration in the US and the UK. Genzyme generated sales of around $4.5 billion, has 10,000 employees and spends $800 million on R&D. Genzyme's leading products are Cerezyme (imiglucerase for injection) for Gaucher disease ($793 million sales 2009); Sevelamer (Renagel and Renvela) for renal disease ($707 million sales 2009); Fabrazyme (agalsidase beta) for Fabry disease ($431 million sales 2009) and Synvisc (hylan G-F 20) for osteoarthritis of the knee ($329 million sales).

Click here to view more report details: http://www.companiesandmarkets.com/Company-Profile/sanofi...

Author: Paul Chapman, Analyst

# # #

Browse 450,000 market research reports and company profiles covering major markets, companies and countries. www.companiesandmarkets.com is a central source of market research reports from the world’s leading analysts and report publishers.